Zoetis announced today its recent acquisition of the marketing rights for Loncor® 300 (florfenicol) from Elanco. With Loncor 300, Zoetis adds an amphenicol option to its market-leading cattle anti-infective portfolio.1
“Bovine respiratory disease, BRD, continues to be a challenge for beef and dairy producers,” said Mitch Blanding, DVM, beef technical services for Zoetis. “In our anti-infective product line, we have demonstrated efficacy with products like Draxxin® KP (tulathromycin and ketoprofen injection) Injectable Solution and Excede® (ceftiofur crystalline free acid) Sterile Suspension. Loncor 300 gives producers another option to treat BRD and adds a fourth class of antibiotic to our portfolio of products.”
Loncor 300 (florfenicol) is a broad-spectrum antibiotic active against many Gram-negative and Gram-positive bacteria that cause bovine respiratory disease and foot rot.
“Loncor gives veterinarians and cattle producers an additional tool within the Zoetis portfolio when treating respiratory disease,” Dr. Blanding said. “As a product sold by Zoetis, Loncor will also be backed by the expertise and insights our people have with bovine respiratory disease and helping keep cattle healthy.”
Zoetis will begin marketing Loncor 300 in the first quarter 2025. New packaging for Loncor 300 will come to market later in 2025.
For more information on the full line of cattle anti-infective products from Zoetis visit
IMPORTANT SAFETY INFORMATION: Do not use Loncor in animals that have shown hypersensitivity to florfenicol. Not for use in animals intended for breeding; not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Do not use in calves to be processed for veal. Preslaughter withdrawal time is 28 days following last intramuscular administration or 38 days following last subcutaneous administration. See full prescribing information here.
IMPORTANT SAFETY INFORMATION: Draxxin KP has a pre-slaughter withdrawal time of 18 days in cattle. Not for use in female dairy cattle 1 year of age or older, including dry dairy cows. Not for use in beef calves less than 2 months of age, pre-weaned dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in animals previously found to be hypersensitive to tulathromycin and ketoprofen. See full Prescribing Information at draxxinkp.com/pi.
IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Excede. Excede is contraindicated in animals with known allergy to ceftiofur or to the ß-lactam group (penicillins and cephalosporins) of antimicrobials. Inadvertent intra-arterial injection is possible and fatal. Do not use in calves to be processed for veal. Pre-slaughter withdrawal time is 13 days following the last dose. See full Prescribing Information at excede.com/pi.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
